SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Borg J) srt2:(2020-2024)"

Sökning: WFRF:(Borg J) > (2020-2024)

  • Resultat 1-10 av 102
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • 2021
  • swepub:Mat__t
  •  
2.
  • Campbell, PJ, et al. (författare)
  • Pan-cancer analysis of whole genomes
  • 2020
  • Ingår i: Nature. - : Springer Science and Business Media LLC. - 1476-4687 .- 0028-0836. ; 578:7793, s. 82-
  • Tidskriftsartikel (refereegranskat)abstract
    • Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.
  •  
3.
  •  
4.
  • Drake, TM, et al. (författare)
  • Surgical site infection after gastrointestinal surgery in children: an international, multicentre, prospective cohort study
  • 2020
  • Ingår i: BMJ global health. - : BMJ. - 2059-7908. ; 5:12
  • Tidskriftsartikel (refereegranskat)abstract
    • Surgical site infection (SSI) is one of the most common healthcare-associated infections (HAIs). However, there is a lack of data available about SSI in children worldwide, especially from low-income and middle-income countries. This study aimed to estimate the incidence of SSI in children and associations between SSI and morbidity across human development settings.MethodsA multicentre, international, prospective, validated cohort study of children aged under 16 years undergoing clean-contaminated, contaminated or dirty gastrointestinal surgery. Any hospital in the world providing paediatric surgery was eligible to contribute data between January and July 2016. The primary outcome was the incidence of SSI by 30 days. Relationships between explanatory variables and SSI were examined using multilevel logistic regression. Countries were stratified into high development, middle development and low development groups using the United Nations Human Development Index (HDI).ResultsOf 1159 children across 181 hospitals in 51 countries, 523 (45·1%) children were from high HDI, 397 (34·2%) from middle HDI and 239 (20·6%) from low HDI countries. The 30-day SSI rate was 6.3% (33/523) in high HDI, 12·8% (51/397) in middle HDI and 24·7% (59/239) in low HDI countries. SSI was associated with higher incidence of 30-day mortality, intervention, organ-space infection and other HAIs, with the highest rates seen in low HDI countries. Median length of stay in patients who had an SSI was longer (7.0 days), compared with 3.0 days in patients who did not have an SSI. Use of laparoscopy was associated with significantly lower SSI rates, even after accounting for HDI.ConclusionThe odds of SSI in children is nearly four times greater in low HDI compared with high HDI countries. Policies to reduce SSI should be prioritised as part of the wider global agenda.
  •  
5.
  • Barnes, DR, et al. (författare)
  • Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
  • 2022
  • Ingår i: Journal of the National Cancer Institute. - : Oxford University Press (OUP). - 1460-2105 .- 0027-8874. ; 114:1, s. 109-122
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundRecent population-based female breast cancer and prostate cancer polygenic risk scores (PRS) have been developed. We assessed the associations of these PRS with breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers.Methods483 BRCA1 and 1318 BRCA2 European ancestry male carriers were available from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). A 147-single nucleotide polymorphism (SNP) prostate cancer PRS (PRSPC) and a 313-SNP breast cancer PRS were evaluated. There were 3 versions of the breast cancer PRS, optimized to predict overall (PRSBC), estrogen receptor (ER)–negative (PRSER-), or ER-positive (PRSER+) breast cancer risk.ResultsPRSER+ yielded the strongest association with breast cancer risk. The odds ratios (ORs) per PRSER+ standard deviation estimates were 1.40 (95% confidence interval [CI] =1.07 to 1.83) for BRCA1 and 1.33 (95% CI = 1.16 to 1.52) for BRCA2 carriers. PRSPC was associated with prostate cancer risk for BRCA1 (OR = 1.73, 95% CI = 1.28 to 2.33) and BRCA2 (OR = 1.60, 95% CI = 1.34 to 1.91) carriers. The estimated breast cancer odds ratios were larger after adjusting for female relative breast cancer family history. By age 85 years, for BRCA2 carriers, the breast cancer risk varied from 7.7% to 18.4% and prostate cancer risk from 34.1% to 87.6% between the 5th and 95th percentiles of the PRS distributions.ConclusionsPopulation-based prostate and female breast cancer PRS are associated with a wide range of absolute breast and prostate cancer risks for male BRCA1 and BRCA2 carriers. These findings warrant further investigation aimed at providing personalized cancer risks for male carriers and informing clinical management.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  • Rheinbay, E, et al. (författare)
  • Analyses of non-coding somatic drivers in 2,658 cancer whole genomes
  • 2020
  • Ingår i: Nature. - : Springer Science and Business Media LLC. - 1476-4687 .- 0028-0836. ; 578:7793, s. 102-
  • Tidskriftsartikel (refereegranskat)abstract
    • The discovery of drivers of cancer has traditionally focused on protein-coding genes1–4. Here we present analyses of driver point mutations and structural variants in non-coding regions across 2,658 genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium5 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). For point mutations, we developed a statistically rigorous strategy for combining significance levels from multiple methods of driver discovery that overcomes the limitations of individual methods. For structural variants, we present two methods of driver discovery, and identify regions that are significantly affected by recurrent breakpoints and recurrent somatic juxtapositions. Our analyses confirm previously reported drivers6,7, raise doubts about others and identify novel candidates, including point mutations in the 5′ region of TP53, in the 3′ untranslated regions of NFKBIZ and TOB1, focal deletions in BRD4 and rearrangements in the loci of AKR1C genes. We show that although point mutations and structural variants that drive cancer are less frequent in non-coding genes and regulatory sequences than in protein-coding genes, additional examples of these drivers will be found as more cancer genomes become available.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 102
Typ av publikation
tidskriftsartikel (89)
konferensbidrag (9)
forskningsöversikt (2)
rapport (1)
Typ av innehåll
refereegranskat (87)
övrigt vetenskapligt/konstnärligt (13)
populärvet., debatt m.m. (1)
Författare/redaktör
Borg, Åke (26)
Borg, J. (19)
Borg, A (16)
Ringnér, Markus (16)
Staaf, Johan (16)
Peterlongo, P (14)
visa fler...
Hamann, U (14)
Andrulis, IL (14)
Radice, P (14)
Nevanlinna, H (14)
Chenevix-Trench, G (14)
Schmutzler, RK (14)
Antoniou, AC (14)
Southey, MC (13)
Manoukian, S (13)
Toland, AE (13)
Simard, J (13)
Easton, DF (13)
John, EM (13)
McGuffog, L. (13)
Rantala, J. (13)
Wappenschmidt, B. (13)
Engel, C. (13)
Neuhausen, SL (13)
Tischkowitz, M (13)
Leslie, G (13)
Hahnen, E (13)
Dennis, J (12)
Yannoukakos, D (12)
Thomassen, M. (12)
Osorio, A. (12)
Stoppa-Lyonnet, D. (12)
Offit, K. (12)
Montagna, M. (12)
Caligo, MA (12)
Godwin, AK (12)
Claes, KBM (12)
Domchek, SM (12)
Janavicius, R (12)
Benitez, J. (11)
Couch, FJ (11)
Jakubowska, A (11)
Singer, CF (11)
Goldgar, DE (11)
Bonanni, B. (11)
Barrowdale, D (11)
Karlan, BY (11)
Diez, O (11)
Greene, MH (11)
Hulick, PJ (11)
visa färre...
Lärosäte
Karolinska Institutet (80)
Lunds universitet (41)
Uppsala universitet (15)
Kungliga Tekniska Högskolan (12)
Göteborgs universitet (10)
Umeå universitet (7)
visa fler...
RISE (3)
Stockholms universitet (2)
Örebro universitet (2)
Gymnastik- och idrottshögskolan (2)
Luleå tekniska universitet (1)
Högskolan i Halmstad (1)
Linköpings universitet (1)
Malmö universitet (1)
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
Högskolan Dalarna (1)
Röda Korsets Högskola (1)
visa färre...
Språk
Engelska (100)
Svenska (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (59)
Naturvetenskap (10)
Teknik (3)
Lantbruksvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy